Neisseria Meningitidis Patents (Class 424/250.1)
  • Patent number: 10668142
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 2, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 10617766
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Patent number: 10266572
    Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: April 23, 2019
    Assignee: Children's Hospital & Research Center At Oakland
    Inventor: Peter T. Beernink
  • Patent number: 10196429
    Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: February 5, 2019
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
  • Patent number: 10064932
    Abstract: The invention provides a method for immunizing a patient, comprising administering multiple conjugates meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 4, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cameron John Marshall
  • Patent number: 9943592
    Abstract: Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: April 17, 2018
    Assignee: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Xiuzhi Susan Sun, Jishu Shi
  • Patent number: 9623101
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: April 18, 2017
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 9579372
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 28, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Patent number: 9475864
    Abstract: The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against Neisseria meningitidis. The invention also provides kits for carrying out these screens, and improved vaccines against Neisseria meningitidis.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 25, 2016
    Assignee: University of Massachusetts
    Inventors: Sanjay Ram, Tathagat Duttaray, Peter A. Rice, Lisa A. Lewis, Sunita Gulati
  • Patent number: 9468673
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 18, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Patent number: 9402915
    Abstract: Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 2, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Cameron John Marshall
  • Patent number: 9365624
    Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: June 14, 2016
    Assignees: GlaxoSmithKline Biologicals, S.A., Utrecht University
    Inventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants
  • Patent number: 9266942
    Abstract: Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: February 23, 2016
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Peter Beernink
  • Patent number: 9173955
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: November 3, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Patent number: 9168293
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: October 27, 2015
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 9156894
    Abstract: NMB1870 is a protein in Neisseria meningitidis. Three families of NMB1870 are known. To increase the ability of a NMB1870 protein to elicit antibodies that are cross-reactive between the families, NMB1870 is engineered. Sequences can be substituted from one NMB1870 family into the corresponding position in another family. Proteins of NMB1870 sequences from different families can be joined to each other.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 13, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Vega Masignani, Maria Scarselli, Rino Rappuoli, Mariagrazia Pizza, Marzia Monica Giuliani
  • Patent number: 9107873
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: August 18, 2015
    Assignee: Wyeth Holdings LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 9057716
    Abstract: The disclosure provides compositions, methods and kits for assessing immunogenicity, potency, or both, of meningococcal capsular saccharide vaccines. The assessment is based upon measurement of binding of a bactericidal antibody to a capsular saccharide component in the vaccine.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: June 16, 2015
    Assignee: Novartis AG
    Inventors: Cristiana Balocchi, Enrico Luzzi, Marilena Paludi, Marzia Monica Giuliani, John Donnelly, Elena Mori
  • Publication number: 20150147356
    Abstract: A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other. Paracetamol significantly reduces fever rates without negatively affecting the immunogenicity either of a meningococcal vesicle vaccine or of concomitantly-administered antigens.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 28, 2015
    Inventors: Alan Kimura, Peter Dull
  • Patent number: 9034345
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: May 19, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 9011869
    Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than I. Proteins where each of the n-X— moieties shares sequence identity to each other —X— moiety, the protein is a ‘tandem protein’.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: April 21, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Mariagrazia Pizza
  • Patent number: 8999354
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 7, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Patent number: 8986710
    Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: March 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
  • Patent number: 8980286
    Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: March 17, 2015
    Assignee: Novartis AG
    Inventors: Maurizio Comanducci, Mariagrazia Pizza
  • Patent number: 8968748
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 3, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 8956625
    Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Publication number: 20140341890
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LUCENTIS® (ranibizumab), BEXSERO® (meningococcal group B vaccine [rDNA, component, adsorbed]), AIN457 (secukinumab) or RELAXIN® (serelaxin).
    Type: Application
    Filed: April 23, 2014
    Publication date: November 20, 2014
    Applicant: CORNING INCORPORATED
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 8889152
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: November 18, 2014
    Assignee: Novartis AG
    Inventor: Paolo Costantino
  • Patent number: 8883163
    Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 11, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Patent number: 8858958
    Abstract: An immunological adjuvant comprises an aluminum salt, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be included in a composition with an immunogen e.g. to elicit an immune response that protects against a bacterial disease or a fungal disease.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Michele Pallaoro, Derek O'Hagan, Rino Rappuoli
  • Patent number: 8852606
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 7, 2014
    Assignee: Novartis AG
    Inventor: Paolo Costantino
  • Publication number: 20140294935
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 2, 2014
    Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
  • Publication number: 20140287043
    Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
    Type: Application
    Filed: April 23, 2012
    Publication date: September 25, 2014
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo Omenetto
  • Patent number: 8840907
    Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis Vaccines and Diagnostics S.r.l.
    Inventor: Mariagrazia Pizza
  • Patent number: 8834888
    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: September 16, 2014
    Assignee: Novartis AG
    Inventors: Mario Contorni, Lorenzo Tarli
  • Publication number: 20140186399
    Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: President and Fellows of Harvard College
    Inventor: John J. MEKALANOS
  • Patent number: 8765135
    Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: July 1, 2014
    Assignee: Novartis AG
    Inventor: Mario Contorni
  • Patent number: 8753651
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from the serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventor: Paolo Costantino
  • Patent number: 8741314
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: June 3, 2014
    Assignee: Sanofi Pasteur, Inc.
    Inventor: Robert P. Ryall
  • Publication number: 20140147469
    Abstract: The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vaccines, to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response.
    Type: Application
    Filed: July 5, 2012
    Publication date: May 29, 2014
    Applicant: De Staat der Nederlanden, vert. door de minister van VWS Ministerie van Volksgezondheid, Welzjin en
    Inventors: Bas Van De Waterbeemd, Leonardus Aldolfus Van Der Pol
  • Patent number: 8734812
    Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Cesira Galeotti, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
  • Patent number: 8734813
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 27, 2014
    Assignee: Sanofi Pasteur, Inc.
    Inventor: Robert P. Ryall
  • Patent number: 8722062
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: May 13, 2014
    Assignee: Sanofi Pasteur, Inc.
    Inventor: Robert P. Ryall
  • Publication number: 20130344106
    Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Inventors: ANDRE E. NEL, HYON-JEEN KIM
  • Publication number: 20130330295
    Abstract: The disclosure relates to antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against human bacterial pathogens.
    Type: Application
    Filed: February 7, 2012
    Publication date: December 12, 2013
    Inventor: Jon Sayers
  • Patent number: 8591917
    Abstract: Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP, showing advantages due to the less aggressive reaction in the site of injection and can be used in a simpler way and better for the patients.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: November 26, 2013
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Luis Enrique Fernández Molina, Circe Mesa Pardillo
  • Patent number: 8580279
    Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: November 12, 2013
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
  • Publication number: 20130295164
    Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 7, 2013
    Inventors: Jean Haensler, Bruno Guy
  • Patent number: 8574597
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 5, 2013
    Assignee: Wyeth LLC
    Inventor: Gary Warren Zlotnick
  • Patent number: RE45137
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 16, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante